Roughly 35 years after early patient data suggested the potential of tumor-infiltrating lymphocytes (TIL) in cancer, Iovance Biotherapeutics Inc. received U.S. FDA approval for lifileucel, marking both the first autologous TIL cell therapy for commercial use and the first one-time cell therapy for a solid tumor cancer. Branded Amtagvi, lifileucel is cleared for use in patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor
Work at Abbisko Therapeutics Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.
Shouyao Holdings (Beijing) Co. Ltd. has patented tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer and Noonan syndrome.
Baylor College of Medicine has disclosed new neurotrophic receptor tyrosine kinase (NTRK) inhibitors that are reported to be useful for the treatment of cancer, endometriosis, female infertility, pelvic pain and inflammatory disorders.
Since oxaliplatin is currently one of the most effective chemotherapeutic drugs used in the treatment of colorectal cancer (CRC), resistance to oxaliplatin usually leads to therapeutic failure and poor prognosis in CRC patients. A team at The Sixth Affiliated Hospital - Sun Yat-sen University aimed to investigate the mechanisms of metabolic reprogramming in oxaliplatin resistance in CRC.
In a recent study, scientists from Medical University of South Carolina aimed to evaluate whether immunogenic cell death (ICD) can trigger resistance to anticancer therapies and explore potential therapeutic opportunities to revive ICD and restore drug sensitivity.
Zapata Computing Inc. (Zapata AI) scientists have demonstrated the first instance of a generative model running on quantum hardware outperforming state-of-the-art classical models in generating viable cancer drug candidates.
Anadolu University and Atatürk University have jointly described novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds acting as carbonic anhydrase type I and/or type II inhibitors.
A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer.
Because selective BET inhibitors present better efficacy and safety than pan-BET inhibitors, current research is focused on the development of BD1- or BD2-selective inhibitors.
RSS
